Verona Pharma PLC (VRNA)
13.03
-0.33
(-2.47%)
USD |
NASDAQ |
May 17, 16:00
13.03
0.00 (0.00%)
After-Hours: 18:20
Verona Pharma Cash from Financing (Quarterly): -3.123M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -3.123M |
| December 31, 2023 | 24.01M |
| September 30, 2023 | 0.048M |
| June 30, 2023 | 0.124M |
| March 31, 2023 | 68.68M |
| December 31, 2022 | 2.614M |
| September 30, 2022 | 139.62M |
| June 30, 2022 | -0.689M |
| March 31, 2022 | -0.726M |
| December 31, 2021 | -0.901M |
| September 30, 2021 | -1.817M |
| June 30, 2021 | -3.399M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 3.95M |
| September 30, 2020 | 188.39M |
| Date | Value |
|---|---|
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.372M |
| September 30, 2019 | -0.1591M |
| June 30, 2019 | -0.1033M |
| March 31, 2019 | -0.1096M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.742M |
| September 30, 2017 | 2.078M |
| June 30, 2017 | 83.97M |
| March 31, 2017 | -1.321M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.399M
Minimum
Jun 2021
188.39M
Maximum
Sep 2020
20.84M
Average
--
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | -0.0533M |
| TC BioPharm (Holdings) PLC | -- |
| Bicycle Therapeutics PLC | 1.871M |
| Adaptimmune Therapeutics PLC | 0.074M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -13.61M |
| Cash from Investing (Quarterly) | -0.016M |
| Free Cash Flow | -58.07M |
| Free Cash Flow Per Share (Quarterly) | -0.1688 |
| Free Cash Flow Yield | -5.57% |